Michael Gillmeister

Title: Michael Gillmeister: Innovator in Recombinant AAV Production

Introduction

Michael Gillmeister is a notable inventor based in Hanover, MD (US). He has made significant contributions to the field of biotechnology, particularly in the production of recombinant Adeno-Associated Virus (rAAV) particles. His innovative methods have the potential to enhance the efficiency of rAAV production, which is crucial for various therapeutic applications.

Latest Patents

Gillmeister holds a patent for a "Scalable method for recombinant AAV production." This patent outlines improved methods for producing rAAV particles. The method involves culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor. Additionally, it includes the use of an increased amount of a sodium salt to further enhance production efficiency. He has 1 patent to his name.

Career Highlights

Michael Gillmeister is associated with Regenxbio Inc., a company that focuses on gene therapy and the development of innovative treatments. His work at Regenxbio has positioned him as a key player in advancing gene therapy technologies.

Collaborations

Some of his notable coworkers include Miguel Valle and Bhargavi Kondragunta. Their collaborative efforts contribute to the innovative environment at Regenxbio, fostering advancements in biotechnology.

Conclusion

Michael Gillmeister's contributions to the field of recombinant AAV production exemplify the impact of innovation in biotechnology. His work not only enhances production methods but also paves the way for future advancements in gene therapy.